Recap: Affimed Q3 Earnings
Affimed (NASDAQ:AFMD) reported its Q3 earnings results on Tuesday, November 14, 2023 at 06:30 AM. Here’s what investors…
Earnings Outlook For Affimed
Affimed (NASDAQ:AFMD) is set to give its latest quarterly earnings report on Tuesday, 2023-11-14. Here’s what investors need…
Why BEST Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Gainers
Carbon Revolution Public Limited (NASDAQ: CREV) shares surged 358% to $134.37 in pre-market trading after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge Capital Acquisition Corp.
Affimed Announces Oral Presentation Of Phase 1/2 Data From AFM13 In Combination With Allogeneic NK Cells At The 2023 ASH Annual Meeting
In 36 patients with CD30-positive lymphoma treated at the recommended Phase 2 dose level (RP2D), the combination treatment of AFM13 with allogeneic NK cells shows a 94.4% objective response rate and a 72.2% complete
What 6 Analyst Ratings Have To Say About Affimed
Over the past 3 months, 6 analysts have published their opinion on Affimed (NASDAQ:AFMD) stock. These analysts are…
Affimed Wins FDA Fast Track Designation for AFM13 in Combination with AlloNK for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma
Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the FDA
Expert Ratings for Affimed
Affimed (NASDAQ:AFMD) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Affimed Announced Publication In The Journal mAbs On Leveraging FcRn-pH-HPLC As A Method To Select Bispecific Antibodies With Optimal Developability
Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the
Where Affimed Stands With Analysts
Affimed (NASDAQ:AFMD) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell
• IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.